Clinical Trial Update: Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of ipilimumab and GVAX in metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• GVAX Prostate Cancer Vaccine (GM-CSF expressing tumor cell vaccine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED